$GILD BREAKOUT ON THE WAY IN GILEAD SCIENCES INCGilead traded well today on the news it will be investing $5.1 billion in EURONEXT:GLPG which will raise its stake from 12% to 22% with the a future target of 29.9% ownership on approval by the shareholders of Galapagos. The market seems happy with the move, even as biotech stocks have been under pressure lately. Decisions out of the White House haven't been helping, as the government continues to keep a close eye on drug prices.
Also on Monday Wells Fargo analysts upgraded Gilead Sciences to an outperform rating and slapped an $88 price target on the name. That implies 33% upside from Friday's closing price and would send Gilead stock more than 10% above its 52-week high.
AVERAGE ANALYSTS PRICE TARGET $88
AVERAGE ANALYSTS RECOMMENDATION OVERWEIGHT
P/E RATIO 15
SHORT INTEREST 1%
Company Description
Gilead Sciences , Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. Its primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands.
GILD trade ideas
$GILD Time to be BULLISH on Gilead Sciences.Gilead reported earnings on Thursday and it may be finally turning the corner. GILD was considered a one trick pony due to the success of its Hepatitis drugs, which unfortunately have starting to drop in revenue. That decline has been meet with a rising revenue stream from new HIV treatments, which tend to be longer term treatments than Hepatitis cases. As a result of recent acquisitions, Oncology is also a growing revenue stream with Yescarta more than doubling revenue to $96m in the first quarter. GILEAD also has a sizable cash at hand of $30 Billion along with a very strong balance sheet. Analysts have a overweight rating on the stock and a average price target of $81, we expect some upgrades in the days to come. NASDAQ:GILD
Company Description
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. Its primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands.
Gilead Sciences - earnings after the bellGilead Sciences, Inc. is expected to report earnings after market close. According to Zacks Investment Research, based on 7 analysts' forecasts, the consensus EPS forecast for the quarter is $1.53. The reported EPS for the same quarter last year was $1.37.
Gilead under performed the XBI - S&P Biotech ETF since Q3 2016. Horizontal support at $60.32 will be a key technical level to watch out for.
GILD: Sort opportunityAn intraday high potential, Back Tested Sort Analysis.
We ll try to enter into the correction of the uptrend movement.
DETAILS ON THE CHART
NOTE: Entry range area above the entry point, is calculated upon 80% of the recorded pullback back tested past performances
DISCLAIMER: This is a technical analysis study, not an advice or recommendation to invest money on.